Literature DB >> 34430525

A combined Cox and logistic model provides accurate predictive performance in estimation of time-dependent probabilities for recurrence of intrahepatic cholangiocarcinoma after resection.

Seogsong Jeong1,2, Guijuan Luo2,3, Qiang Gao4, Jing Chen2,3, Xiaolong Liu5, Liangqing Dong4, Yongjie Zhang6, Feng Shen7, Qingbao Cheng8, Chengjun Sui9, Jingfeng Liu5, Hongyang Wang2,3, Qiang Xia1, Lei Chen2,10.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma has heterogeneous outcomes after resection. There remains a need for broadly applicable recurrence-specific tool offering precise evaluation on curativeness of resection.
METHODS: A four hospital-based clinical cohort involving 1,655 patients with intrahepatic cholangiocarcinoma who received surgical resection were studied. Cox and logistic models were networked into one system containing risk categories with distinctive probabilities of recurrence. Prediction of time-to-recurrence was performed by formulizing time-dependent risk probabilities. The model was validated in three clinical cohorts (n=332).
RESULTS: From the training cohort, 10 and 11 covariates, including diabetes, cholelithiasis, albumin, platelet count, alpha fetoprotein, carbohydrate antigen 19-9, carcinoembryonic antigen, hepatitis B virus infection, tumor size and number, resection type, and lymph node metastasis, from Cox and logistic models were identified significant for recurrence-free survival (RFS). The combined Cox & logistic ranking system (CCLRS)-adjusted time-dependent probabilities were categorized into seven ranks (5-yr RFS for lowest and highest ranks were 75% vs. 0%; hazard ratio 18.5, 95% CI: 14.7-24.9, P<0.0001). The CCLRS was validated with a minimum area under curve value of 0.8086. Prediction of time-to-recurrence was validated to be excellent (Pearson r, 0.8204; P<0.0001).
CONCLUSIONS: The CCLRS allows precise estimation on risk of recurrence for intrahepatic cholangiocarcinoma after resection. It could be applicative when estimating time-dependent disease status and stratifying individuals who sole resection of the tumor would not be curative. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Primary liver cancer; biliary malignancy; hepatectomy; nomogram; regression model; resection; surgery

Year:  2021        PMID: 34430525      PMCID: PMC8351002          DOI: 10.21037/hbsn.2020.01.07

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  31 in total

1.  Nationwide multicenter study aimed at the establishment of common reference intervals for standardized clinical laboratory tests in Japan.

Authors:  Yoshikazu Yamamoto; Shigemi Hosogaya; Susumu Osawa; Kiyoshi Ichihara; Toshimitsu Onuma; Atsushi Saito; Kouji Banba; Hideo Araki; Yasunori Nagamine; Katsuyuki Shinohara; Gen Okada; Hiroyuki Matsumoto; Takashi Oguri; Satoko Gonaikawa; Miyuki Iwagami
Journal:  Clin Chem Lab Med       Date:  2013-08       Impact factor: 3.694

Review 2.  Intrahepatic cholangiocarcinoma: new insights in pathology.

Authors:  Christine Sempoux; Ghalib Jibara; Stephen C Ward; Cathy Fan; Lihui Qin; Sasan Roayaie; M Isabel Fiel; Myron Schwartz; Swan N Thung
Journal:  Semin Liver Dis       Date:  2011-02-22       Impact factor: 6.115

3.  The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Fabio Bagante; Katiuscha Merath; Malcolm H Squires; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-01-19       Impact factor: 3.452

Review 4.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 5.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

Review 6.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

7.  A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.

Authors:  Omar Hyder; Hugo Marques; Carlo Pulitano; J Wallis Marsh; Sorin Alexandrescu; Todd W Bauer; T Clark Gamblin; Georgios C Sotiropoulos; Andreas Paul; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Irinel Popescu; Jean-Francois Gigot; Gilles Mentha; Shen Feng; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2014-05       Impact factor: 14.766

Review 8.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  BMJ       Date:  2015-01-07

9.  Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma.

Authors:  Chenyue Zhang; Haiyong Wang; Zhouyu Ning; Litao Xu; Liping Zhuang; Peng Wang; Zhiqiang Meng
Journal:  Onco Targets Ther       Date:  2017-03-06       Impact factor: 4.147

10.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Authors:  Supriya K Saha; Andrew X Zhu; Charles S Fuchs; Gabriel A Brooks
Journal:  Oncologist       Date:  2016-03-21
View more
  3 in total

1.  Logistic Model and Gradient Boosting Machine Model for Physical Therapy of Lumbar Disc Herniation.

Authors:  Ping Zhao; Jin Xue; Xiaomei Xu; Lifei Wang; Dan Chen
Journal:  Comput Math Methods Med       Date:  2022-05-11       Impact factor: 2.809

2.  A Nomogram Model to Predict Early Recurrence of Patients With Intrahepatic Cholangiocarcinoma for Adjuvant Chemotherapy Guidance: A Multi-Institutional Analysis.

Authors:  Qi Li; Jian Zhang; Chen Chen; Tianqiang Song; Yinghe Qiu; Xianhai Mao; Hong Wu; Yu He; Zhangjun Cheng; Wenlong Zhai; Jingdong Li; Dong Zhang; Zhimin Geng; Zhaohui Tang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model.

Authors:  Changcan Li; Bao Jin; Hang Sun; Yunchao Wang; Haitao Zhao; Xinting Sang; Huayu Yang; Yilei Mao
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.